Enjaymo Den europeiske union - norsk - EMA (European Medicines Agency)

enjaymo

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - immunsuppressive - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Euthyrox 25 mikrog Norge - norsk - Statens legemiddelverk

euthyrox 25 mikrog

merck ab (1) - levotyroksinnatrium - tablett - 25 mikrog

Euthyrox 50 mikrog Norge - norsk - Statens legemiddelverk

euthyrox 50 mikrog

merck ab (1) - levotyroksinnatrium - tablett - 50 mikrog

Euthyrox 100 mikrog Norge - norsk - Statens legemiddelverk

euthyrox 100 mikrog

merck ab (1) - levotyroksinnatrium - tablett - 100 mikrog

Calquence Den europeiske union - norsk - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - leukemi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Esomeprazol Orifarm 10 mg Norge - norsk - Statens legemiddelverk

esomeprazol orifarm 10 mg

orifarm generics a/s - esomeprazolmagnesium - enterogranulat til mikstur, suspensjon i dosepose - 10 mg

Iressa Den europeiske union - norsk - EMA (European Medicines Agency)

iressa

astrazeneca ab - gefitinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - iressa er indisert for behandling av voksne pasienter med lokalt avansert eller metastatisk ikke-liten celle lunge kreft med aktiverende mutasjoner av epidermal vekst-faktor-reseptor tyrosin kinase.

Silgard Den europeiske union - norsk - EMA (European Medicines Agency)

silgard

merck sharp dohme ltd - humant papillomavirus type 6 l1 protein, humant papillomavirus type 11 l1 protein, humant papillomavirus type 16 l1 protein, humant papillomavirus type 18 l1 protein - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vaksiner - silgard er en vaksine for bruk fra alder av 9 år for forebygging av:premalignant genitale lesjoner (cervical, vulva og vagina), premalignant anal lesjoner, cervical kreft og anal kreft uformelt knyttet til enkelte oncogenic humant papillomavirus (hpv) type;kjønnsvorter (condyloma acuminata) causally knyttet til spesifikke hpv-typer. se avsnitt 4. 4 og 5. 1 for viktig informasjon om dataene som støtter denne indikasjonen. bruk av silgard skal være i samsvar med offisielle anbefalinger.

Retsevmo Den europeiske union - norsk - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Den europeiske union - norsk - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaksiner - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.